Three Dow components are out with earnings this morning, and all three companies telling a similar story: a beat on earnings but a miss on revenue. The pattern was most pronounced with Travelers (TRV). Excluding items, it posted earnings of $2.13 when estimates were for $1.60. But revenue was about $150-million below estimates. Dupont (DD) also missed slightly on revenue, surprising with less than $10-billion. It did however beat on earnings by a penny. United Technologies (UTX) posted earnings of $1.70 a share compared with estimates of $1.57. But revenue was missed failing to rise above $16-billion in sales.

Today's also the day Apple (AAPL) reports after the closing bell. The stock has been up fractionally for most of the morning, hovering in the mid 420s. This is of course one of the few stocks that has failed to rally this year, even with earnings that are ho-hum. Yahoo! Finance Senior Columnist Mike Santoli has more in the video above.

Now we have some more earnings just released this morning: Lockheed Martin (LMT) had a nice beat on both the top and bottom lines with earnings 20% above estimates. Altria (MO) missed on both the top and bottom, but not by much with earnings of 62-cents on $4.5 billion. Finally, UPS (UPS) which warned last week, matched on earnings estimates with $1.13 a share, but it missed slightly on revenue.

First prostitution and bribery. Now what's described as a drug maker’s "mortal sin." The New York Times says GlaxoSmithKline (GSK) is accused of violating medical ethics at a research facility in China. The accusations include a failure to properly monitor clinical trials. Also, not reporting results of animal studies for a drug already being tested on humans. Charges of wrongdoing first surfaced last week with the Chinese government accusing executives of an elaborate kickback scheme involving hookers and travel agencies. Shares of Glaxo are down less than half a percent over the past week as the scandal has grown. The company reports earnings tomorrow.

STOCKS TO WATCH

First up is the same company we started with yesterday: Netflix (NFLX). Shares have been down as much as 6.4% since the company reported earnings after the closing bell. It's a bit surprising when you see how the company performed compared to estimates. It matched on revenue of $1.07 billion and reported earnings of 49-cents a share, more than 20% above expectations. The main problem: original programming like House of Cards and Arrested Development failed to lift subscriptions as much as predicted. Reality also seems to be setting in that Netflix has been losing content from partners like Viacom. Netflix shares are up 185% year-to-date, but one analyst with Wedbush Securities warns that without a pickup in subscriptions, shares could tumble in half.

Next up is Texas Instruments (TXN) which also reported earning after the closing bell. It's currently trading 3% higher. The company managed a slight beat on earnings. Excluding items it posted profits of 42-cents a share, a penny better than expected. It did however miss on revenue, which was down 9% from a year ago. Most important perhaps was that profit was up 48% from a year ago on both cost-cutting and rising demand for computer chips from automakers and industrial companies. Shares of Texas Instruments are up 40% over the past year.

Dow component AT&T (T) reports after today's closing bell. The company is expected to see small increases over a year ago with earnings of 68-cents a share on $31.81 billion in revenue. The company has been looking for ways to grow amid a maturing market. Last week it unveiled a pay-as-you-go plan that eliminates two-year contracts for smartphones. AT&T is up about 2% year-to-date, and under 1% over the past year.

Finally we look at drug maker Onyx (ONXX) which is was up more than 2% yesterday amid new rumblings of takeover attempts. That means shares have now climbed 58% over the past month, largely on a bid from Amgen. Bloomberg reports that now AstraZeneca (AZN) and Novartis (NVS) are preparing offers for Onyx. It says Pfizer (PFE) is also weighing an offer although Reuters says that's not going to happen. California-based Onyx specializes in cancer treatments.